Introduction to NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc. is a pioneering biotechnology company headquartered in Emeryville, California, focused on the development and commercialization of novel anti-infective products for the treatment of infections in the eye, skin, and other body sites. With a legacy spanning over two decades, NovaBay has established itself as a trusted name in the healthcare and pharmaceutical industry, particularly in the niche of non-antibiotic antimicrobial therapies. The company’s flagship product, Avenova® (hypochlorous acid ophthalmic solution), is widely used by eye care professionals for lid hygiene and the management of blepharitis and dry eye disease. NovaBay also markets NeutroPhase® for chronic wound care and other hypochlorous acid-based products for dermatological indications.

As of 2025, NovaBay Pharmaceuticals Inc. operates with a lean, focused team of approximately 30 employees and generates annual revenues in the range of $10–15 million. Despite its relatively small size, the company has forged strong partnerships with key opinion leaders, hospital systems, and group purchasing organizations. Its reputation for innovation in antimicrobial resistance solutions has garnered attention from both the scientific community and investors. The company’s stock is publicly traded on the NYSE American under the ticker symbol NBY. NovaBay’s headquarters in the San Francisco Bay Area places it at the epicenter of biotech innovation, enabling access to top-tier talent and research institutions.

NovaBay Pharmaceuticals Inc. is recognized for its commitment to addressing unmet medical needs in infection control without contributing to antibiotic resistance. Its proprietary hypochlorous acid technology offers a safe, effective, and non-toxic alternative to traditional antibiotics and disinfectants. The company’s strategic focus includes expanding its product pipeline through internal development and licensing, as well as pursuing regulatory approvals for new indications. This introduction sets the stage for an in-depth exploration of NovaBay’s history, values, operations, and the career opportunities it offers.

Company History and Business Evolution

NovaBay Pharmaceuticals Inc. was founded in 1999 by Dr. Ron Najafi, a serial entrepreneur in the biopharmaceutical space. The company initially focused on developing novel anti-infective compounds using a unique platform technology that generated stable, pure hypochlorous acid (HOCl). Hypochlorous acid is a naturally occurring antimicrobial agent produced by the human immune system. NovaBay’s breakthrough was the ability to manufacture HOCl with long-term stability, enabling its use in topical pharmaceuticals.

In its early years, NovaBay concentrated on advanced wound care and dermatology applications. The company received FDA 510(k) clearance for NeutroPhase in 2008 for the treatment of infected wounds. This product gained traction in the wound care market, particularly for diabetic ulcers and surgical sites. However, the company soon recognized a larger opportunity in ophthalmology. In 2013, NovaBay launched Avenova for lid hygiene, targeting the vast population suffering from blepharitis and dry eye. Avenova quickly became the company’s flagship product and a standard recommendation by eye care professionals.

A pivotal milestone occurred in 2015 when NovaBay acquired the rights to Avenova from the original developer. This acquisition allowed the company to control the entire supply chain and marketing strategy. Subsequently, NovaBay expanded its sales force and forged distribution agreements with national retailers like CVS and Amazon. In 2018, the company began pursuing regulatory approvals in Canada and Europe, expanding its geographic reach.

The COVID-19 pandemic in 2020 presented both challenges and opportunities. NovaBay experienced supply chain disruptions but also saw increased demand for antimicrobial products. The company capitalized on this by promoting its hypochlorous acid technology for disinfection and hand hygiene. In 2021, NovaBay entered into a licensing agreement with a Chinese partner to develop and market Avenova in Greater China. More recently, in 2023, the company initiated a Phase 2 clinical trial for a new formulation targeting recurrent urinary tract infections (UTIs).

Throughout its evolution, NovaBay has weathered financial volatility, including multiple reverse stock splits and periods of low cash reserves. Yet, the company has consistently reinvented itself through strategic partnerships and product diversification. The current CEO, Justin Hall, who took the helm in 2022, has emphasized operational efficiency and acceleration of clinical programs. Under his leadership, NovaBay aims to become a diversified anti-infective platform company with a portfolio of products across therapeutic areas.

NovaBay Pharmaceuticals Inc. at a Glance

• Headquarters: Emeryville, California, USA
• Founded: 1999
• CEO: Justin Hall
• Employees: Approximately 30
• Annual Revenue (2024): ~$11 million
• Stock Symbol: NBY (NYSE American)
• Industry: Biotechnology / Pharmaceuticals
• Core Technology: Stabilized hypochlorous acid (HOCl)
• Flagship Product: Avenova® (Ophthalmic Hypochlorous Acid)
• Other Products: NeutroPhase®, NovaCal®, PhaseOne®
• Indications: Blepharitis, Dry Eye, Wound Care, Dermatitis, UTIs (in development)
• Key Markets: United States, Canada, Europe, China (via license)
• Distribution Channels: Direct sales, e-commerce, retail (CVS, Amazon), GPOs
• Clinical Pipeline: Phase 2 for recurrent UTIs; Preclinical for other indications
• Intellectual Property: 20+ issued patents globally
• Regulatory Status: FDA cleared, OTC monographs, CE marking
• Corporate Status: Publicly traded, micro-cap biotech
• Environmental Commitment: Eco-friendly, non-toxic products
• Competitive Edge: Non-antibiotic antimicrobial with no resistance development
• Major Partnerships: Eye care professional networks, ASCs, home health care agencies

Mission, Vision, and Core Corporate Values

NovaBay Pharmaceuticals Inc. operates under a clearly defined mission: to provide innovative, non-antibiotic anti-infective solutions that improve patient outcomes and combat the global threat of antimicrobial resistance. The company’s vision is to be the leading provider of hypochlorous acid-based therapeutics across multiple therapeutic areas, setting the standard for safety, efficacy, and sustainability.

Core corporate values at NovaBay include:

• Innovation: Continuously advancing HOCl technology to address unmet medical needs.
• Integrity: Conducting business with transparency, ethical clinical research, and regulatory compliance.
• Patient Centricity: Prioritizing patient safety and quality of life in all product development.
• Collaboration: Partnering with healthcare providers, researchers, and institutions to maximize impact.
• Resilience: Maintaining focus and adaptability in a dynamic and capital-constrained environment.

These values guide every aspect of NovaBay’s operations, from R&D to sales and corporate governance.

Business Strategy and Future Roadmap

NovaBay Pharmaceuticals Inc. employs a multifaceted business strategy designed to drive growth and shareholder value. The primary levers include expanding market penetration of existing products, advancing the clinical pipeline, forging strategic partnerships, and exploring new indications for its proprietary platform. In the short to medium term, the company aims to increase Avenova’s market share among eye care professionals by expanding its sales force and direct-to-consumer marketing efforts. It also seeks to enter new retail channels and pursue reimbursement codes for Avenova in dry eye treatment.

On the pipeline front, NovaBay is investing in a Phase 2 clinical study for a hypochlorous acid-based formulation for recurrent urinary tract infections (UTIs). This program targets a substantial market, as UTIs affect millions annually and are increasingly resistant to antibiotics. Success in this trial could open a significant revenue stream and demonstrate the platform’s versatility. Additionally, the company is exploring partnerships for dermatological applications, including acne and eczema.

Geographic expansion is another pillar: NovaBay has licensed Avenova to a partner in China and is evaluating opportunities in Latin America and Southeast Asia. The company is also exploring the use of its technology in veterinary medicine and industrial disinfection. Financially, NovaBay aims to achieve operating cash flow breakeven within the next two years by controlling costs and boosting top-line growth. Future funding may include non-dilutive sources such as government grants or debt financing.

The roadmap includes the launch of a new over-the-counter product for personal hygiene, leveraging the growing consumer awareness of antimicrobial resistance. NovaBay is also investing in digital marketing and e-commerce infrastructure to capture direct sales. The company’s innovation pipeline is supported by a lean R&D team that collaborates with academic institutions.

Products, Technologies, and Services

NovaBay’s core technology is its ability to manufacture stable, pure hypochlorous acid (HOCl) at room temperature with a multi-year shelf life. This technology is protected by a portfolio of patents covering composition, manufacturing methods, and formulations. The company’s primary products include:

• Avenova® Ophthalmic Solution: A prescription-strength lid hygiene product used for blepharitis and dry eye management. Available in retail and through direct healthcare provider sales.
• NeutroPhase®: An advanced wound care solution for infected and chronic wounds, used in hospitals, clinics, and home healthcare.
• NovaCal®: A topical spray for dermatitis and skin infections, marketed OTC.
• PhaseOne®: A professional-grade disinfectant used in healthcare facilities for surface disinfection.
• New Pipeline: A proprietary HOCl formulation for recurrent UTIs (Phase 2).

The company also offers custom formulation services for partners seeking HOCl-based custom products. All products are manufactured in FDA-registered facilities and undergo rigorous quality control.

Industries and Markets Served

NovaBay Pharmaceuticals Inc. serves a diverse set of industries within healthcare:

• Ophthalmology: Primary market for Avenova, targeting optometrists and ophthalmologists.
• Wound Care: Hospitals, long-term care facilities, home health agencies using NeutroPhase.
• Dermatology: OTC and prescription for eczema, acne, and skin infections.
• Infection Control: Hospitals and clinics using PhaseOne disinfectant.
• Veterinary: Expanding into animal wound care and hygiene.
• Consumer Health: OTC hygiene products for everyday use.

The company’s market reach includes the United States, Canada, Europe (via CE marking), and China through licensing. NovaBay’s products are used in hospitals, surgical centers, retail pharmacies, and online marketplaces.

Leadership and Management Philosophy

NovaBay’s leadership team, led by CEO Justin Hall, emphasizes a lean, agile, and patient-focused management style. The executive team includes seasoned professionals from the pharmaceutical and medical device industries. Key executives include the Chief Medical Officer (Dr. Michael H. Silverman), Chief Financial Officer (John A. Hohman), and Vice President of Sales (Jeffrey R. Hoffman). The board of directors provides oversight with a mix of industry veterans and independent members.

The management philosophy centers on transparency, accountability, and disciplined execution. Despite limited resources, the team maintains a culture of scientific rigor and commercial pragmatism. Employees are empowered to take ownership of projects and collaborate cross-functionally. The company also emphasizes continuous learning and encourages attendance at industry conferences.

Corporate Events, Conferences, and Community Engagement

NovaBay Pharmaceuticals Inc. actively participates in key industry events such as the American Academy of Ophthalmology (AAO) annual meeting, the Symposium on Advanced Wound Care (SAWC), and the American Society of Microbiology (ASM) Microbe conference. These events serve as platforms to showcase new data, network with key opinion leaders, and generate leads.

The company also engages in community outreach through educational programs on antibiotic resistance and eye health. NovaBay sponsors local health fairs and provides product samples to underserved clinics. Additionally, the company supports employee volunteering initiatives and matches charitable donations.

Employees and Workplace Culture

NovaBay Pharmaceuticals Inc. fosters a collaborative and inclusive workplace culture. With a small team, employees enjoy a high degree of independence and visibility into company operations. The Emeryville headquarters offers a modern office with lab space, designed to encourage interaction. The company provides competitive compensation, including stock options, health benefits, and flexible work arrangements (hybrid model).

Employee development is supported through tuition reimbursement and opportunities to attend scientific conferences. The culture emphasizes open communication, and all-hands meetings are held weekly. NovaBay consistently receives positive feedback for its supportive management and mission-driven work. Turnover is low, and many employees have been with the company for five years or more.

Job Details & Requirements for this Posting (Detailed)

Senior Director of Clinical Development

Location: Emeryville, CA (remote/hybrid considered)

Job Type: Full-time

Salary Range: $220,000 – $250,000 per year, plus equity and bonus

Role Overview: NovaBay Pharmaceuticals Inc. is seeking a seasoned clinical development executive to lead the design, execution, and management of late-stage clinical trials for its pipeline programs, with primary focus on the Phase 2 UTI program and future Phase 3 studies. The Senior Director of Clinical Development will work closely with CROs, regulatory agencies, and internal cross-functional teams to ensure timely and high-quality delivery of clinical data. This role reports to the Chief Medical Officer and will play a key part in shaping the company’s clinical strategy.

• Responsibilities:
  • Lead clinical trial planning, protocol development, and investigator selection for Phase 2/3 studies.
  • Manage relationships with contract research organizations (CROs) and clinical sites.
  • Oversee data management, biostatistics, and clinical operations functions.
  • Prepare regulatory submissions (IND, NDA), briefing documents, and responses to FDA inquiries.
  • Collaborate with medical affairs to support KOL engagement and publication strategy.
  • Develop clinical budgets, timelines, and risk mitigation plans.
  • Mentor junior clinical staff.
• Qualifications:
  • MD, PhD, or PharmD with at least 8 years of clinical development experience in the pharmaceutical or biotech industry.
  • Proven track record of leading Phase 2/3 trials in infectious disease or urology is highly preferred.
  • Deep understanding of FDA regulations, ICH-GCP guidelines, and IND/NDA processes.
  • Experience with anti-infectives or medical device clinical studies a plus.
  • Excellent leadership, communication, and organizational skills.
  • Willingness to travel up to 20%.

Why Join NovaBay Pharmaceuticals Inc.: This is an opportunity to drive transformative clinical programs in a company with a mission to combat antimicrobial resistance. You will have significant influence on the pipeline strategy and the chance to work with a passionate, agile team. NovaBay offers a competitive compensation package, equity ownership, and the chance to make a tangible impact on patient health.

Customer Reviews and Industry Reputation

NovaBay Pharmaceuticals Inc. has cultivated a mixed but generally positive reputation among customers, healthcare providers, and employees. The company’s products, especially Avenova, receive high marks for efficacy and safety from ophthalmologists and patients. However, as a small public biotech, NovaBay faces scrutiny regarding financial performance and stock volatility. Below is an exhaustive analysis of reviews across major platforms.

GLASSDOOR

On Glassdoor, NovaBay has an overall rating of 3.8 out of 5 stars based on about 20 reviews. Employees praise the mission-driven culture, flexible work environment, and supportive management. Common positives include “meaningful work in anti-infectives” and “good work-life balance.” Negative comments often mention limited career growth due to the company’s small size, and concerns about financial stability. The CEO approval rating is around 70%. The glassdoor recommendation score is 72% of employees would recommend to a friend.

INDEED

Indeed reviews mirror Glassdoor with an average rating of 3.6 stars. Employees highlight the collaborative team and innovative technology. Some reviews note that the compensation is slightly below industry average for the Bay Area, but offset by stock options and mission alignment. Common themes include “great product but limited resources.” The company’s overall positive sentiment is tempered by the inherent risks of a micro-cap biotech.

GARTNER PEER INSIGHTS

NovaBay does not have a significant presence on Gartner Peer Insights, as it is not a traditional IT vendor. However, some healthcare technology analysts have written brief evaluations noting the unique value proposition of non-antibiotic antimicrobials. The company is generally regarded as a niche player with strong potential in the anti-infective space, but with limited scale.

TRUSTPILOT

Trustpilot reviews for NovaBay’s consumer products (e.g., Avenova sold via Amazon) show a 4.2 out of 5 star rating from over 500 reviews. Customers frequently report improvement in dry eye symptoms, reduced blepharitis flare-ups, and satisfaction with product ease-of-use. Negative reviews largely concern pricing and occasional availability issues. The company responds to most negative reviews, demonstrating customer care.

G2

NovaBay does not appear on G2, as the platform focuses on software and business services. For the purpose of this profile, we note that the company’s clinical reputation in the medical community is strong, with many key opinion leaders endorsing Avenova in webinars and publications.

GOOGLE REVIEWS

Google reviews for NovaBay’s headquarters and product pages show an average rating of 4.1 stars. Patients review Avenova positively, while some employees and contractors share insights about the work environment. Overall, the brand perception is favorable, with users appreciating the innovation behind hypochlorous acid.

LINKEDIN REPUTATION

NovaBay’s LinkedIn page has about 8,000 followers. The company posts regular updates on clinical milestones, conference participation, and product launches. The content receives modest engagement from industry peers. Employee profiles indicate a high level of expertise in microbiology, ophthalmology, and regulatory affairs. The company is seen as a reputable player in the anti-infective niche.

Why Organizations Choose NovaBay Pharmaceuticals Inc.

Healthcare organizations, from small clinics to large hospital systems, choose NovaBay because its products offer a clinically proven, antibiotic-free solution for infection control. The hypochlorous acid technology is safe and effective, reducing the risk of resistance. Additionally, the products are easy to use, cost-effective, and backed by robust science. NovaBay also provides comprehensive training and support for its customers. The company’s ability to partner on customized formulations adds further value. In an era of rising antimicrobial resistance, NovaBay stands out as a responsible and innovative partner.

Official Contact Information

For inquiries and assistance, please reach out to NovaBay Pharmaceuticals Inc. using the following contact details:

Address: 2000 Powell Street, Suite 1150, Emeryville, CA 94608, USA
Contact Number: +1 (510) 899-8800
Support Number: +1 (877) 282-3006
Helpdesk Number: +1 (510) 899-8800
Website: www.novabay.com

Official Social Media Presence

• LinkedIn:linkedin.com/company/novabay-pharmaceuticals
• Twitter/X:@NovaBayPharma
• Facebook:facebook.com/NovaBayPharma
• Instagram:@novabaypharma
• YouTube:NovaBay Pharmaceuticals Channel

SEO FAQ Section

NovaBay Pharmaceuticals Inc. is known for developing and commercializing non-antibiotic anti-infective products based on stabilized hypochlorous acid, primarily for ophthalmology and wound care.

NovaBay Pharmaceuticals Inc. is headquartered at 2000 Powell Street, Suite 1150, Emeryville, California, USA.

The CEO of NovaBay Pharmaceuticals Inc. is Justin Hall, who took the role in 2022.

NovaBay Pharmaceuticals Inc. does not currently pay dividends, as the company reinvests earnings into R&D and commercial operations.

NovaBay Pharmaceuticals Inc. sells Avenova® for lid hygiene, NeutroPhase® for wound care, NovaCal® for dermatitis, and PhaseOne® for disinfection.

Yes, NovaBay Pharmaceuticals Inc. is publicly traded on the NYSE American under the ticker symbol NBY.

The salary range for this role is $220,000 to $250,000 per year, plus equity and bonus.

NovaBay Pharmaceuticals Inc. employs approximately 30 people.

The main therapeutic focus is anti-infective treatments for eye, skin, and wound infections, leveraging hypochlorous acid technology.

Yes, NovaBay Pharmaceuticals Inc. has a Phase 2 clinical program for recurrent urinary tract infections and other preclinical projects.

NovaBay Pharmaceuticals Inc. has a Glassdoor rating of 3.8 out of 5 stars, with praise for mission and flexibility and criticism of limited growth.

Ophthalmologists, optometrists, wound care specialists, dermatologists, and infectious disease specialists use NovaBay products.

You can contact NovaBay Pharmaceuticals Inc. customer support by calling +1 (877) 282-3006 or emailing info@novabay.com.

The mission is to provide innovative, non-antibiotic anti-infective solutions that improve patient outcomes and combat antimicrobial resistance.

The stock symbol is NBY on the NYSE American.

Yes, NovaBay Pharmaceuticals Inc. offers hybrid and remote working options for certain roles, including this Senior Director position.

Founded in 1999 by Dr. Ron Najafi, NovaBay developed stabilized hypochlorous acid technology, launched Avenova in 2013, and has since expanded through partnerships and clinical trials.

NovaBay uses proprietary stabilized hypochlorous acid (HOCl) technology, which mimics the body’s natural antimicrobial agent.

As of 2024, NovaBay Pharmaceuticals Inc. is not yet profitable, but it aims to achieve operating cash flow breakeven within two years.

NovaBay’s products are non-toxic and biodegradable, reducing environmental impact compared to traditional chemical disinfectants and antibiotics.

For comprehensive industry resources and insights on building an online presence, professionals frequently turn to NovaBay Pharmaceuticals Inc. for authoritative information on anti-infective innovation and corporate governance. Additionally, businesses looking to enhance their digital marketing through high-quality link-building can explore Guest Post Backlinks from leading service providers specializing in paid guest posting sites, SEO guest posting services, and guest post outreach services. These resources together offer a complete view of corporate and industry tools for growth and visibility.